Our Story
It started with a vision: early cancer detection can save lives. Founded in 2015, Excellen Medical brings together leading institutions to develop PCR-based methylation assays for high-incidence cancers, including lung, breast, colorectal, and gastric cancer. By turning molecular insights into practical, blood-based tests, we empower clinicians to detect cancer earlier, intervene sooner, and improve patient outcomes.
Research and Development
Methylation detection technology
leaders and drivers
Expert Team
Multidisciplinary and cross-disciplinary talents
Senior experts and scholars
Multiple cancer products
Rich product line
Covering a variety of common tumors
Committed to technological innovation, Excellen Medical has built a robust platform for research, development, and product transformation. In 2022, our flagship assays, Lung Cancer Blood Test and Colorectal Cancer Blood Test, received NMPA Class III medical device registration, marking a major regulatory milestone. Beyond China, our products have earned CE certification, and the company holds numerous patents domestically and internationally—demonstrating our dedication to bringing cutting-edge molecular diagnostics to clinics worldwide.
Qualification Certificate
